p27Kip1

SX53G8, Ms

Artikelnummer:P2010-H
Menge:
Technische Daten
Change(s) made:Complete revision
Status:In Vitro Diagnostic Use (IVD)
Spezies:Mouse
Ig Unterklasse:IgG1/k
Immunogen:p27Kip1 Protein
Vorbehandlung:ProTaqs® Antigen Enhancer I (Cat. No. 401602092) or ProTaqs® Antigen Enhancer IV (Cat. No. 401602392)
Zelluläre Lokalisation:Nuclear
Kontrolle:Tonsil
Synonyme:CDN1B_HUMAN, AA408329, AI843786, Cdki1b, CDKN 1B, CDKN 4, CDKN1B, CDKN1B, CDKN4, CDKN4, Cyclin Dependent Kinase Inhibitor 1B, Cyclin Dependent Kinase Inhibitor 1B, Cyclin dependent kinase inhibitor p27, Cyclin dependent kinase inhibitor p27, Cyclin-dependent kinase inhibitor 1B (p27, Kip1), Cyclin-dependent kinase inhibitor 1B, Cyclin-dependent kinase inhibitor p27, Cyclin-dependent kinase inhibitor p27 Kip1, KIP 1, KIP1, MEN1B, MEN4, OTTHUMP00000195098, OTTHUMP00000195099, p27, p27 Kip1, P27-like cyclin-dependent kinase inhibitor, P27KIP1.
Verfügbar in folgenden Ländern:worldwide
Beschreibung

p27 is a cyclin-dependent kinase inhibitor which regulates progression from G1 to S phase by binding and inhibiting cyclin-dependent kinases. Low expression has been associated with unfavorable prognosis in renal cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in Papillary carcinoma of the thyroid, and more aggressive phenotype in carcinoma of the cervix.

Literatur

Kontakt